Immune checkpoint inhibitor myocarditis

被引：17

作者：

Raikhelkar, Jayant ^{[1
]}

Uriel, Nir ^{[1
]}

机构：

[1] Univ Chicago, Div Cardiol, Chicago, IL 60637 USA

来源：

CURRENT OPINION IN CARDIOLOGY | 2019年 / 34卷 / 03期

关键词：

cardio-oncology; cardiotoxicity; immune checkpoint inhibitor; myocarditis; FULMINANT MYOCARDITIS; MANAGEMENT; DIAGNOSIS; SURVIVAL; THERAPY;

D O I：

10.1097/HCO.0000000000000622

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Purpose of review The purpose of this study is to summarize and highlight the recent literature regarding immune checkpoint inhibitor myocarditis. Recent findings The use of immune checkpoint inhibitors, a promising form of immunotherapy, is rapidly increasing in oncology. These drugs have been recently found to cause a fulminant myocarditis associated with a high-case fatality rate. Most patients present early in the course of treatment with positive cardiac biomarkers. Endomyocardial biopsy findings resemble high-grade cardiac transplant rejection. Treatment requires cessation of immunotherapy, aggressive immunosuppression, and hemodynamic stabilization. Summary Immune checkpoint inhibitor myocarditis is a newly described entity. Although relatively uncommon compared with other immune-related adverse events associated with these drugs, it is associated with the highest rate of mortality.

引用

页码：303 / 306

页数：4

共 24 条

[1] Reporting of immune checkpoint inhibitor-associated myocarditis [J].

Al-Kindi, Sadeer G. ;

Oliveira, Guilherme H. .

LANCET, 2018, 392 (10145) :382-383

[2] The clinical trial landscape for PD1/PDL1 immune checkpoint inhibitors [J].

Tang, Jun ;

Yu, Jia Xin ;

Lin, Yunqing .

NATURE REVIEWS DRUG DISCOVERY, 2018, 17 (12) :854-854

[3]

[Anonymous], 2014, J Clin Oncol abstr, V32, p5s, DOI DOI 10.1200/JCO.2014.32.15_SUPPL.3064

[4] Survival After Fulminant Myocarditis Induced by Immune-Checkpoint Inhibitors [J].

Arangalage, Dimitri ;

Delyon, Julie ;

Lermuzeaux, Mathilde ;

Ekpe, Kenneth ;

Ederhy, Stephane ;

Pages, Cecile ;

Lebbe, Celeste .

ANNALS OF INTERNAL MEDICINE, 2017, 167 (09) :683-684

[5] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

[6] Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases [J].

Caforio, Alida L. P. ;

Pankuweit, Sabine ;

Arbustini, Eloisa ;

Basso, Cristina ;

Gimeno-Blanes, Juan ;

Felix, Stephan B. ;

Fu, Michael ;

Helio, Tiina ;

Heymans, Stephane ;

Jahns, Roland ;

Klingel, Karin ;

Linhart, Ales ;

Maisch, Bernhard ;

McKenna, William ;

Mogensen, Jens ;

Pinto, Yigal M. ;

Ristic, Arsen ;

Schultheiss, Heinz-Peter ;

Seggewiss, Hubert ;

Tavazzi, Luigi ;

Thiene, Gaetano ;

Yilmaz, Ali ;

Charron, Philippe ;

Elliott, Perry M. .

EUROPEAN HEART JOURNAL, 2013, 34 (33) :2636-+

[7] Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure -: Results of the Anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial [J].

Chung, ES ;

Packer, M ;

Lo, KH ;

Fasanmade, AA ;

Willerson, JT .

CIRCULATION, 2003, 107 (25) :3133-3140

[8] Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy [J].

Eggermont, A. M. M. ;

Chiarion-Sileni, V. ;

Grob, J. -J. ;

Dummer, R. ;

Wolchok, J. D. ;

Schmidt, H. ;

Hamid, O. ;

Robert, C. ;

Ascierto, P. A. ;

Richards, J. M. ;

Lebbe, C. ;

Ferraresi, V. ;

Smylie, M. ;

Weber, J. S. ;

Maio, M. ;

Bastholt, L. ;

Mortier, L. ;

Thomas, L. ;

Tahir, S. ;

Hauschild, A. ;

Hassel, J. C. ;

Hodi, F. S. ;

Taitt, C. ;

de Pril, V. ;

de Schaetzen, G. ;

Suciu, S. ;

Testori, A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) :1845-1855

[9] Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma [J].

Eggermont, Alexander M. M. ;

Blank, Christian U. ;

Mandala, Mario ;

Long, Georgina, V ;

Atkinson, Victoria ;

Dalle, Stephane ;

Haydon, Andrew ;

Lichinitser, Mikhail ;

Khattak, Adnan ;

Carlino, Matteo S. ;

Sandhu, Shahneen ;

Larkin, James ;

Puig, Susana ;

Ascierto, Paolo A. ;

Rutkowski, Piotr ;

Schadendorf, Dirk ;

Koornstra, Rutger ;

Hernandez-Aya, Leonel ;

Maio, Michele ;

van den Eertwegh, Alfonsus J. M. ;

Grob, Jean-Jacques ;

Gutzmer, Ralf ;

Jamal, Rahima ;

Lorigan, Paul ;

Ibrahim, Nageatte ;

Marreaud, Sandrine ;

van Akkooi, Alexander C. J. ;

Suciu, Stefan ;

Robert, Caroline .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (19) :1789-1801

[10] Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity [J].

Escudier, Marion ;

Cautela, Jennifer ;

Malissen, Nausicaa ;

Ancedy, Yann ;

Orabona, Morgane ;

Pinto, Johan ;

Monestier, Sandrine ;

Grob, Jean-Jacques ;

Scemama, Ugo ;

Jacquier, Alexis ;

Lalevee, Nathalie ;

Barraud, Jeremie ;

Peyrol, Michael ;

Laine, Marc ;

Bonello, Laurent ;

Paganelli, Franck ;

Cohen, Ariel ;

Barlesi, Fabrice ;

Ederhy, Stephane ;

Thuny, Franck .

CIRCULATION, 2017, 136 (21) :2085-2087

← 1 2 3 →